Evaluation of a Bacillus -Based Direct-Fed Microbial on Aflatoxin B1 Toxic Effects, Performance, Immunologic Status, and Serum Biochemical Parameters in Broiler Chickens.

The aim of the present study was to evaluate the effect of a commercial Bacillus direct-fed microbial (DFM) on aflatoxin B1 toxic effects, performance, and biochemical and immunologic parameters in broiler chickens. Ninety 1-day-old Cobb 500 male broiler chicks were raised in floor pens for a period of 21 days. Chicks were neck-tagged, individually weighed, and randomly allocated to one of three groups: Negative control (basal feed), aflatoxin B1 (basal feed + 2 ppm AFB1), and DFM (basal feed + 2 ppm AFB1 + Bacillus direct-fed microbial). Each group had three replicates of 10 chickens (n = 30/group). Body weight and body weight gain were calculated weekly, while feed intake and feed conversion ratio were determined when broilers were 21 days old. On day 21, all chickens were bled, gastrointestinal samples were collected, and spleen and bursa of Fabricius were weighed. This study confirmed that 2 ppm of AFB1 causes severe detrimental effects on performance, biochemical parameters, and immunologic parameters, generating hepatic lesions in broiler chickens (P < 0.05). However, it was also observed that DFM supplementation provided beneficial effects that might help to improve gut barrier function, anti-inflammatory and antioxidant activities, as well as humoral and cellular immunomodulation. The results of the present study suggest that this Bacillus-DFM added at a concentration of 106 spores/gram of feed can be used to counteract the negative effects that occur when birds consume diets contaminated with AFB1, showing beneficial effects on performance parameters, relative organ weights, hepatic lesions, immune response, and serum biochemical variables. The addition of this Bacillus-DFM might mitigate and decrease aflatoxicosis problems in the poultry industry, improving food security, alleviating public health problems, and providing economic benefits. Future studies are needed to fully elucidate the specific mechanisms by which this Bacillus-DFM counteracts the toxic effects of aflatoxin B1.

Evaluación de un producto comercial adicionado en el alimento elaborado con Bacillus sobre los efectos tóxicos de la aflatoxina B1, el rendimiento productivo, el estado inmunológico y los parámetros bioquímicos en suero de pollos de engorde. El objetivo del presente estudio fue evaluar el efecto de un producto comercial de Bacillus adicionado al alimento (DFM) sobre los efectos tóxicos de la aflatoxina B1, el rendimiento productivo, así como en los parámetros bioquímicos e inmunológicos en pollos de engorde. Noventa pollitos de engorde machos Cobb 500 de un día de edad fueron criados en corrales en piso por un período de 21 días. Los pollos se etiquetaron en el cuello, se pesaron individualmente y se asignaron al azar en uno de tres grupos: control negativo (alimentación basal); aflatoxina B1 (alimentación basal + 2 ppm de AFB1) y DFM (alimentación basal + 2 ppm de AFB1 + producto comercial de Bacillus). Cada grupo tenía tres réplicas de 10 pollos (n = 30/grupo). El peso corporal (BW) y la ganancia de peso corporal (BWG) se calcularon semanalmente, mientras que la ingesta de alimento (FI) y la conversión alimentaria (FCR) se determinaron cuando los pollos tenían 21 días de edad. Al día 21 de edad, todos los pollos se sangraron, se recolectaron muestras gastrointestinales y se pesaron el bazo y la bolsa de Fabricio. Este estudio confirmó que 2 ppm de aflatoxina B1 causan efectos detrimentales graves sobre los parámetros productivos, bioquímicos e inmunológicos, generando lesiones hepáticas en pollos de engorde (P < 0.05). Sin embargo, también se observó que la suplementación con el producto comercial de Bacillus proporcionó efectos benéficos que podrían ayudar a mejorar la función de la barrera intestinal, las actividades antiinflamatorias y antioxidantes, así como la inmunomodulación humoral y celular. Los resultados del presente estudio sugieren que este producto comercial de Bacillus agregado a una concentración de 106 esporas/gramo de alimento puede usarse para contrarrestar los efectos negativos que se producen cuando las aves consumen dietas contaminadas con aflatoxina B1, mostrando efectos beneficiosos en los parámetros productivos, peso relativo de órganos, lesiones hepáticas, respuesta inmune y variables bioquímicas séricas. La adición de este Bacillus podría mitigar y disminuir los problemas de aflatoxicosis en la industria avícola, mejorando la seguridad alimentaria, los problemas de salud pública y los beneficios económicos. Se requieren estudios futuros para dilucidar completamente los mecanismos específicos por los cuales este producto comercial con Bacillus contrarresta los efectos tóxicos de la aflatoxina B1.

Evaluation of the Antimicrobial and Anti-inflammatory Properties of Bacillus-DFM (Norum™) in Broiler Chickens Infected With Salmonella Enteritidis.

Restrictions of in-feed antibiotics use in poultry has pushed research toward finding appropriate alternatives such as Direct-Fed Microbials (DFM). In this study, previously tested Bacillus isolates (B. subtilis and B. amyloliquefaciens) were used to evaluate their therapeutic and prophylactic effects against Salmonella enterica serovar Enteritidis (S. Enteritidis) in broiler chickens. For this purpose, initial antibacterial activity of Bacillus-DFM (104 spores/g or 106 spores/g) against S. Enteritidis colonization in crop, proventriculus and intestine was investigated using an in vitro digestive model. Furthermore, to evaluate therapeutic and prophylactic effects of Bacillus-DFM (104 spores/g) against S. Enteritidis colonization, altogether 60 (n = 30/group) and 30 (n = 15/group) 1-day-old broiler chickens were randomly allocated to either DFM or control group (without Bacillus-DFM), respectively. Chickens were orally gavaged with 104 cfu of S. Enteritidis per chicken at 1-day old, and cecal tonsils (CT) and crop were collected 3 and 10 days later during the therapeutic study, whereas they were orally gavaged with 107 cfu of S. Enteritidis per chicken at 6-day-old, and CT and crop were collected 24 h later from two independent trials during the prophylactic study. Serum superoxide dismutase (SOD), FITC-d and intestinal IgA levels were reported for both chicken studies, in addition cecal microbiota analysis was performed during the therapeutic study. DFM significantly reduced S. Enteritidis concentration in the intestine compartment, and in both proventriculus and intestine compartments as compared to the control when used at 104 spores/g and 106 spores/g, respectively (p < 0.05). DFM significantly reduced FITC-d and IgA as well as SOD and IgA levels (p < 0.05) compared to the control in therapeutic and prophylactic studies, respectively. Interestingly, in the therapeutic study, there were significant differences in bacterial community structure and predicted metabolic pathways between DFM and control. Likewise, phylum Actinobacteria and the genera Bifidobacterium, Roseburia, Proteus, and cc_115 were decreased, while the genus Streptococcus was enriched significantly in the DFM group as compared to the control (MetagenomeSeq, p < 0.05). Thus, the overall results suggest that the Bacillus-DFM can reduce S. Enteritidis colonization and improve the intestinal health in chickens through mechanism(s) that might involve the modulation of gut microbiota and their metabolic pathways.